Vertaling van "since 1 january 2007 there has been " (Nederlands → Frans) :

In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.
In terms of premiums and benefits, since 1 January 2007 there has been a requirement to request a prior licence when a pharmaceutical company or company selling medical devices wishes to pay the costs of a healthcare professional participating in a scientific gathering including at least one overnight stay.

Since 1 January 2007, the law has been in force requiring a preliminary approval for the payment by pharmaceutical companies or producers of medical devices of the participation costs of healthcare professionals in scientific events involving at least one night’s accommodation.
Since 1 January 2007, the law has been in force requiring a preliminary approval for the payment by pharmaceutical companies or producers of medical devices of the participation costs of healthcare professionals in scientific events involving at least one night’s accommodation.

Aclasta/Reclast (USD 254 million), the first once-yearly infusion therapy for various forms of osteoporosis, has now been used in more than 350,000 patients and has experienced consistent growth since its launch to treat postmenopausal osteoporosis in late 2007.
Aclasta/Reclast (USD 254 millions), première injection annuelle pour soigner différentes formes d’ostéoporose, a été utilisé par plus de 350 000 patients et a affiché une croissance notable depuis son lancement, à fin 2007, pour le traitement de l’ostéoporose potsménopausique.

Forward, the Group-wide initiative launched in late 2007 to simplify structures and redesign the way Novartis operates, has been completed a year ahead of schedule after progressing rapidly and achieving more than USD 2.3 billion of cumulative cost savings since 2007 and exceeding its 2010 goal of USD 1.6 billion.
Les économies de coûts cumulées depuis 2007 se montent à plus d’USD 2,3 milliards, dépassant l’objectif d’USD 1,6 milliard en 2010.

The best known energy drink is undoubtedly “Red Bull”, which has been dealt with in numerous discussions in scientific and public health circles since being marketed in Austria in 1987. There is no denying, however, that this sort of drink is a clear commercial success nowadays.
La plus connue des boissons énergisantes est sans conteste le « Red Bull » qui, depuis sa mise au point et sa commercialisation en Autriche en 1987, a fait l’objet de beaucoup de discussions dans les milieux scientifiques et de santé publique.

Exelon/Exelon Patch (USD 251 million, +17% cc) has been driven by Exelon Patch since its first launch in 2007, generating more than 60% of total Exelon sales in the first quarter of 2010 compared to 46% in the 2009 period.
Exelon/Exelon Patch (USD 251 millions, +17% tcc) a été emmené par Exelon Patch depuis son lancement initial en 2007, engendrant plus de 60% du chiffre d’affaires total d’Exelon au premier trimestre 2010 comparé à 46% à la même période de 2009.

Exforge, a single-pill combination of Diovan (valsartan) and the calcium channel blocker amlodipine, has been consistently setting new standards for high blood pressure combination therapies since its first launch in 2007.
Exforge, un comprimé associant Diovan (valsartan) et l’amlodipine, un inhibiteur des canaux calciques, n’a cessé d’établir, depuis son premier lancement en 2007, de nouvelles normes dans le domaine des médicaments combinés pour traiter l’hypertension.

Tekturna/Rasilez (USD 290 million, +104% lc), the first in a new class of medicines known as direct renin inhibitors to treat high blood pressure, has been growing consistently since its launch in 2007 based on positive clinical data demonstrating its prolonged efficacy in lowering blood pressure for more than 24 hours and superiority in clinical trials over ramipril, a leading ACE inhibitor.
Rasilez/Tekturna (USD 290 millions, +104% en m. l.), est le premier d’une nouvelle classe de médicaments, les inhibiteurs directs de la rénine, traitant l’hypertension.